1
|
Larnaudie A, Giraud P, Naessens C, Stefan D, Clavère P, Balosso J. Radiotherapy of skin adnexal carcinoma. Cancer Radiother 2023:S1278-3218(23)00062-8. [PMID: 37080860 DOI: 10.1016/j.canrad.2022.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 12/19/2022] [Accepted: 12/21/2022] [Indexed: 04/22/2023]
Abstract
Skin adnexal carcinomas are rare skin cancer, developing from pilosebaceous, eccrine and apocrine unit. Treatment of localised tumours usually includes surgery and radiotherapy. Indications and modalities of radiotherapy depend on the pathological subtype with a lack of consensus for some histologies. This review summarises the place of radiotherapy in terms of indication, dose and fractionation, volumes to irradiate and discuss ongoing studies.
Collapse
Affiliation(s)
- A Larnaudie
- Department of Radiation Oncology, centre François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France; Department of Radiation Oncology, Dupuytren University Hospital, 2, avenue Martin-Luther-King, 87000 Limoges, France.
| | - P Giraud
- Radiation Oncology, Pitié Salpêtrière, Charles-Foix University Hospital, 47-83, boulevard de l'hôpital, 75013 Paris, France; Médecine Sorbonne universités, 91-105, boulevard de l'hôpital, 75013 Paris, France
| | - C Naessens
- Department of Radiation Oncology, Dupuytren University Hospital, 2, avenue Martin-Luther-King, 87000 Limoges, France
| | - D Stefan
- Department of Radiation Oncology, centre François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France
| | - P Clavère
- Department of Radiation Oncology, Dupuytren University Hospital, 2, avenue Martin-Luther-King, 87000 Limoges, France
| | - J Balosso
- Department of Radiation Oncology, centre François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France
| |
Collapse
|
2
|
Bratu IF, Ribigan AC, Mihailă-Bâldea S, Badea R, Stefan D, Davidoiu C, Casaru B, Antochi F. Febrile episode unmasking neuropsychiatric systemic lupus erythematosus with lytic lesions caused by secondary autoimmune myelofibrosis: Case report. Medicine (Baltimore) 2021; 100:e28251. [PMID: 34941099 PMCID: PMC8702261 DOI: 10.1097/md.0000000000028251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Accepted: 11/25/2021] [Indexed: 11/26/2022] Open
Abstract
RATIONALE Systemic lupus erythematosus (SLE) is characterized by numerous immunological abnormalities that lead to multiorgan involvement. Central and peripheral nervous system manifestations are present in 8% to 92% of the cases of SLE. Furthermore, there have been reported cases of secondary autoimmune myelofibrosis associated with SLE. PATIENT CONCERNS We present the case of a 64-year-old female who was transferred from the Cardiology Department, where she was admitted for pericardial-pleural-peritoneal effusion after being discharged from another hospital following the resolution of a febrile episode. During hospitalization, she presented multiple oculomotor nerves palsies and weakness in the lower limbs. Serial cerebral magnetic resonance imaging (MRI) revealed extensive cerebral venous thrombosis. Nerve conduction studies showed sensory-motor axonal polyneuropathy. Thoracic MRI revealed a rare finding in patients with SLE - lytic lesions. DIAGNOSES Extensive clinical, imaging, blood, and urine tests were performed. The patient exhibited pancytopenia, elevated inflammatory markers, hyperhomocysteinemia, mild hypoproteinemia, and severe proteinuria. The Hematology consultation ascertained that the peripheral blood smear and the bone marrow aspiration showed no alterations suggestive for a primary hematological disease and the thoracic vertebral-medullary MRI changes had a very low probability of representing osteolytic lesions in the context of plasma cells dyscrasia, but could not exclude their being result of a secondary autoimmune myelofibrosis. Immunology blood tests highlighted the presence of antinuclear antibodies and lupus anticoagulants. In this context, the Rheumatology consultation established the diagnosis of SLE with multiple complications. INTERVENTIONS The patient received treatment with cyclophosphamide. OUTCOMES The ocular motricity problems and the paraparesis showed improvement. However, 1 week later, the patient developed weakness, dyspnea, and right lower quadrant abdominal pain. The abdominal-pelvic computed tomography scan indicated an acute right retroperitoneal hematoma with active bleeding for which she underwent arterial embolization of the spinal lumbar arteries with optimal result, but she died a few days later. LESSONS We chose to present this case in order to highlight the importance of interdisciplinarity in diagnosing and managing patients with SLE and multiorgan ailments, especially when faced with rare constellations of complications such as extensive cerebral venous thrombosis and osseous lytic lesions caused by secondary autoimmune myelofibrosis.
Collapse
Affiliation(s)
- Ionuţ-Flavius Bratu
- Department of Neurology, Bucharest Emergency University Hospital, Bucharest, Romania
| | - Athena Cristina Ribigan
- Department of Neurology, Bucharest Emergency University Hospital, Bucharest, Romania
- “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
| | - Sorina Mihailă-Bâldea
- Department of Cardiology, Bucharest Emergency University Hospital, Splaiul Independentei, Bucharest, Romania
- “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
| | - Raluca Badea
- Department of Neurology, Bucharest Emergency University Hospital, Bucharest, Romania
- “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
| | - Daniela Stefan
- Department of Neurology, Bucharest Emergency University Hospital, Bucharest, Romania
- “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
| | - Cristina Davidoiu
- Department of Neurology, Bucharest Emergency University Hospital, Bucharest, Romania
| | - Bogdan Casaru
- Department of Neurology, Bucharest Emergency University Hospital, Bucharest, Romania
| | - Florina Antochi
- Department of Neurology, Bucharest Emergency University Hospital, Bucharest, Romania
| |
Collapse
|
3
|
Ollivier L, Orione C, Champiat S, Lucia F, Misery L, Legoupil D, Pradier O, Bourbonne V, Kacperek C, Stefan A, Stefan D, Thillays F, Rio E, Vaugier L, Lesueur P, Supiot S, Schick U, Kao W. Réponses abscopales chez les patients atteints de mélanome métastatique : étude de cohorte multicentrique nationale. Cancer Radiother 2021. [DOI: 10.1016/j.canrad.2021.07.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
4
|
Bratu IF, Ribigan AC, Stefan D, Davidoiu CR, Badea RS, Antochi FA. Internal Carotid Artery Dissection - A Case for Antithrombotic Therapy in the Era of (Minimally) Invasive Procedures. Maedica (Bucur) 2021; 15:536-542. [PMID: 33603914 DOI: 10.26574/maedica.2020.15.4.536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Objectives: Carotid artery dissection represents a common cause of stroke among people aged 30-45. We present two clinical cases and a review of the literature concerning the management of internal carotid artery dissections (ICADs). Materials and methods: The two patients are a 54-year-old male and a 40-year-old female. The first patient presented to our Neurology Department for one-week-old intense occipital headache. His clinical examination revealed left-sided miosis and upper eyelid ptosis. He underwent cerebral-cervical computed tomography (CT) and computed tomography angiography (CTA) scans and the latter revealed hemodynamically significant narrowing of both ICAs (right C1-C5 and left C1-C2 segments). Transcranial Doppler ultrasonography and Doppler ultrasonography (DUS) of the cervical-cerebral arteries showed right ICA occlusion at its origin (dissection fold and intraluminal thrombosis). Cervical magnetic resonance imaging (MRI) and time-of-flight magnetic resonance angiography (MRA) revealed a semilunar-shaped T2-weighted hypersignal present in the walls of the C1-C5 segments of the right ICA and of the C1-C2 segments of the left ICA, with bilaterally reduced intraluminal flow (right more than left). These findings indicated the presence of bilateral ICA intramural hematomas caused by subacute bilateral ICAD. The second patient presented to our Neurology Department for recurrent episodes of headache and lateral cervical pain on both sides. She underwent transcranial DUS and DUS of the cervicalcerebral arteries. They revealed right ICAD fold in its upper cervical segments. The CTA scan of the supra-aortic trunks showed hemodynamically significant narrowing with subsequent diminished blood flow in the upper cervical segments of right ICA. The patient was diagnosed with right ICAD. Results:Both patients were treated using antiplatelet therapy for primary prevention of ischaemic events. Follow-up at seven months and at six months, respectively, by means of CTA of the supra-aortic trunks or MRA of the cervical region, revealed the restoration of arterial patency with subsequent normal blood flow in both cases. Conclusions: The long-term outcomes of ICADs should be kept in mind when assigning medical or endovascular management on a case-by-case basis. Antiplatelet or anticoagulant therapy is a safe and effective first-line strategy in such patients, especially in cases that do not warrant particular management.
Collapse
Affiliation(s)
| | | | - Daniela Stefan
- Department of Neurology, Emergency University Hospital, Bucharest, Romania
| | | | | | | |
Collapse
|
5
|
Mann P, Stefan D, Katharina S, Christian P K. PO-1596: End-to-end test in MRgRT: 3D dose verification of a gated treatment with a porcine lung phantom. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01614-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Biau J, Thivat E, Chautard E, Stefan D, Boone M, Chauffert B, Bourgne C, Richard D, Molnar I, Levesque S, Bellini R, Kwiatkowski F, Karayan-Tapon L, Verrelle P, Godfraind C, Durando X. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma. Radiother Oncol 2020; 154:227-234. [PMID: 32976869 DOI: 10.1016/j.radonc.2020.09.036] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 09/16/2020] [Accepted: 09/18/2020] [Indexed: 11/18/2022]
Abstract
BACKGROUND AND PURPOSE This phase 1 trial aimed to determine the maximum tolerated dose (MTD; primary objective) of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the treatment of newly diagnosed glioblastoma (GBM) patients. MATERIALS AND METHODS The study was designed as an open-label dose-escalation study driven by a Tite-CRM design and followed by an expansion cohort. Ralimetinib was administered orally every 12 h, 7 days a week, for 2 cycles of 2 weeks at a dose of 100, 200 or 300 mg/12 h. Patients received ralimetinib added to standard concurrent RT (60 Gy in 30 fractions) with TMZ (75 mg/m2/day) and 6 cycles of adjuvant TMZ (150-200 mg/m2 on days 1-5 every 28 days). RESULTS The MTD of ralimetinib was 100 mg/12 h with chemoradiotherapy. The three patients treated at 200 mg/12 h presented a dose-limiting toxicity: one patient had a grade 3 face edema, and two patients had a grade 3 rash and grade 3 hepatic cytolysis (66%). Of the 18 enrolled patients, 15 received the MTD of ralimetinib. At the MTD, the grade ≥ 3 adverse events during concomitant chemoradiotherapy were hepatic cytolysis (2/15 patients), dermatitis/rash (1/15), lymphopenia (1/15) and nausea/vomiting (1/15). No interaction of TMZ and ralimetinib when administrated concomitantly has been observed. Inhibition of pMAPKAP-K2 (-54%) was observed in peripheral blood mononuclear cells. CONCLUSION This phase 1 trial is the first trial to study the combination of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the treatment of newly diagnosed glioblastoma (GBM) patients. The MTD of ralimetinib was 100 mg/12 h. The most frequent dose-limiting toxicities were hepatic cytolysis and rash.
Collapse
Affiliation(s)
- J Biau
- Radiation Department, Centre Jean Perrin, Clermont-Ferrand, France; University of Clermont Auvergne, UFR Médecine, Clermont-Ferrand, France; INSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, France; Centre d'Investigation Clinique UMR 501, Clermont-Ferrand, France.
| | - E Thivat
- INSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, France; Centre d'Investigation Clinique UMR 501, Clermont-Ferrand, France; Department of Clinical Research, Délégation Recherche Clinique et Innovation, Centre Jean Perrin, Clermont-Ferrand, France
| | - E Chautard
- INSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, France; Pathology Department, Centre Jean Perrin, Clermont-Ferrand, France
| | - D Stefan
- Radiation Oncology Department, Centre François Baclesse, Caen, France
| | - M Boone
- Department of Medical oncology, CHU Amiens, France
| | - B Chauffert
- Department of Medical oncology, CHU Amiens, France
| | - C Bourgne
- Department of Biologic hematology, CHU Estaing, Clermont-Ferrand Cedex 1, France
| | - D Richard
- CHU Clermont-Ferrand, University of Clermont-Auvergne, Medical Pharmacology Department, UMR INSERM, Clermont-Ferrand, France
| | - I Molnar
- INSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, France; Centre d'Investigation Clinique UMR 501, Clermont-Ferrand, France; Department of Clinical Research, Délégation Recherche Clinique et Innovation, Centre Jean Perrin, Clermont-Ferrand, France
| | - S Levesque
- INSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, France; Centre d'Investigation Clinique UMR 501, Clermont-Ferrand, France; Department of Clinical Research, Délégation Recherche Clinique et Innovation, Centre Jean Perrin, Clermont-Ferrand, France
| | - R Bellini
- Radiodiagnostic Department, Centre Jean-Perrin, Clermont-Ferrand, France
| | - F Kwiatkowski
- INSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, France; Centre d'Investigation Clinique UMR 501, Clermont-Ferrand, France; Department of Clinical Research, Délégation Recherche Clinique et Innovation, Centre Jean Perrin, Clermont-Ferrand, France
| | - L Karayan-Tapon
- University of Poitiers, INSERMU1084, CHU de Poitiers, Department of Cancer Biology, France
| | - P Verrelle
- Radiation Department, Centre Jean Perrin, Clermont-Ferrand, France; University of Clermont Auvergne, UFR Médecine, Clermont-Ferrand, France; Department of Radiation Oncology, Institut Curie, Paris, France
| | - C Godfraind
- Department of Pathological Anatomy, CHU de Clermont-Ferrand, France
| | - X Durando
- INSERM U1240 IMoST, University of Clermont Auvergne, Clermont-Ferrand, France; Centre d'Investigation Clinique UMR 501, Clermont-Ferrand, France; Department of Clinical Research, Délégation Recherche Clinique et Innovation, Centre Jean Perrin, Clermont-Ferrand, France; Oncology Department, Centre Jean Perrin, Clermont-Ferrand, France; University of Clermont Auvergne, UFR Médecine, Clermont-Ferrand, France
| |
Collapse
|
7
|
Loiseau C, Barraux V, Berejny P, Batalla A, Austins H, Ollivier C, Piantino A, Nicolas C, Stefan D, Kao W, Silva M, Lerouge D. 34 Custom applicators made by 3D printer in brachytherapy: Experience of the F. Baclesse centre (Caen- France). Phys Med 2019. [DOI: 10.1016/j.ejmp.2019.09.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
8
|
Dumont Lecomte D, Lequesne J, Geffrelot J, Lesueur P, Barraux V, Loiseau C, Lacroix J, Leconte A, Émery É, Thariat J, Stefan D. Hypofractionated stereotactic radiotherapy for challenging brain metastases using 36 Gy in six fractions. Cancer Radiother 2019; 23:860-866. [DOI: 10.1016/j.canrad.2019.06.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Revised: 06/10/2019] [Accepted: 06/13/2019] [Indexed: 10/25/2022]
|
9
|
Kissel M, Martel-Lafay I, Lequesne J, Faivre JC, Le Péchoux C, Stefan D, Barraux V, Loiseau C, Grellard JM, Danhier S, Lerouge D, Chouaid C, Gervais R, Thariat J. Irradiation stéréotaxique des oligométastases, oligorécurrences, oligopersistances et oligoprogressions extracérébrales de cancer bronchique. Cancer Radiother 2019. [DOI: 10.1016/j.canrad.2019.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
10
|
Lesueur P, Damaj G, Hoang-Xuan K, Rolland V, Schmitt A, Chinot O, Fabbro M, Agapé P, Chabrot C, Chebrek S, Feuvret L, Stefan D, Soussain C, Houillier C. P14.73 Toxicity and outcomes of reduced-dose whole brain radiotherapy as consolidation treatment for patients with CNS lymphoma in real life setting. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
BACKGROUND
Optimal treatment strategy for newly diagnosed primary PCNSL remains controversial. The high risk of radio-induced late-delayed neurotoxicity in patients who achieve long-term disease control constrains the use of classical consolidation WBRT. So as to reduce side cognitive effects, Morris et al, reported a phase II study, to assess the efficacy and toxicity of consolidation reduced-dose (23.4Gy) WBRT (rdWBRT) for patients with complete response after high dose methotrexate based chemotherapy. The study reported a 2-year PFS rate for these patients of 77%, with no evidence of significant cognitive decline during the follow-up (FU) period. The aim of this retrospective study was to report toxicity and outcomes of rdWBRT, in patients < 60 years old with complete response (CR) after HD-MTX based chemotherapy, in real life setting, without selection bias.
MATERIAL AND METHODS
Patients were selected from the French LOC network database, a nationwide database centralizing since 2011 information from 28 different centers in France, representing the main centers involved in PCNSL management. Patients were retrospectively selected according to the following criteria: 1) Pathological diagnosis of diffuse large B cell PCNSL; 2) age>18 and <60 years; 3) immunocompetent status; 4) First line induction treatment based on high dose MTX (At least MTX>1.5 g/m2); 5) CR according to the IPCG criteria after first-line induction treatment. Patients should have received a rdWBRT (23.4Gy in 13 fractions of 1.8Gy).
RESULTS
Twenty seven patients, were included. The median FU from initial diagnosis was 28.5 months [9.6–50.7]. Median age was 50.2 years [25–60]. Median Karnofsky Performans Status (KPS) was 90% [40–100%]. Seventeen patients had a multi focal disease at diagnosis (meningeal involvement n=6, in ophthalmic involvement n=4). PFS rates were 85% IC95[76–100 %], 65% IC95 [45–85%] and 65% IC95 [45–85%] at 1, 2, and 3 years respectively. The OS rates were 100%, 90,5% IC95 [77–100%] and 85%IC95 [69–100%]. 8 patients relapsed, with a median time from radiotherapy to recurrence of 6.5months [2.4–17]. All recurrences were outside the initially involved site(s), and 62.5% of tumors recurred as multifocal disease. All patients received salvage treatment, including intensive chemotherapy with autologous stem cell transplantation in 4 cases. No acute grade III-IV toxicity related to rdWBRT was reported. Neuropsychological follow up was available for 14 patients with no cognitive impairment at last follow up.
CONCLUSION
This is the largest retrospective study evaluating outcomes of rdWBRT for PCNSL young patients with CR after HD-MTX chemotherapy. Real life setting data from this study are quite reassuring, and rdWBRT could be considered as an efficient and safe consolidation strategy in this population. We need a longer FU to confirm the absence of cognitive deterioration.
Collapse
Affiliation(s)
- P Lesueur
- Centre François Baclesse, Caen, France
| | | | | | | | | | - O Chinot
- Hôpital de la Timône, Marseille, France
| | - M Fabbro
- Institut Régional du Cancer de Montpellier, Montpellier, France
| | - P Agapé
- Institut de Cancerologie de l’Ouest, Nantes, France
| | - C Chabrot
- CHU de Clermont Ferrand, Clermont Ferrand, France
| | | | - L Feuvret
- La Pitié Salpetriere (AP-HP), Paris, France
| | - D Stefan
- Centre François Baclesse, Caen, France
| | | | | |
Collapse
|
11
|
Lecornu M, Silva M, Barraux V, Stefan D, Kao W, Thariat J, Loiseau C. Applicateur numérique par impression tridimensionnelle en curiethérapie de contact. Cancer Radiother 2019; 23:328-333. [DOI: 10.1016/j.canrad.2019.03.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2019] [Revised: 03/01/2019] [Accepted: 03/07/2019] [Indexed: 11/17/2022]
|
12
|
Lequesne J, Dugue A, Licaj I, Lesueur P, Grellard J, Brachet P, Stefan D, Clarisse B. Étude de phase I/IIa évaluant un traitement concomitant par radiothérapie, olaparib et témozolomide chez les patients atteints d’un gliome de haut grade non résécable : méthodologies innovantes, avantages et limites. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
13
|
Martinage G, Geffrelot J, Stefan D, Bogart E, Rault E, Reyns N, Emery E, Martinage Makhloufi S, Mouttet Audouard R, Basson L, Mirabel X, Lartigau E, Pasquier D. EP-1257 Post-operative hypo-fractionated SBRT in a large series of patients with brain metastases. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31677-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Balosso J, Thariat J, Habrand J, Tessonnier T, Lesueur P, Chaikh A, Stefan D, Fontbonne J. SP-0642 How to select patients for radiotherapy with protons instead of photons. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31062-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Lesueur P, Lequesne J, Barraux V, Kao W, Geffrelot J, Habrand JL, Grellard JM, Émery E, Marie B, Thariat J, Stefan D. Radiochirurgie ou radiothérapie en conditions stéréotaxiques hypofractionnée pour les métastases cérébrales de cancer radiorésistant (mélanome et rein) : analyse comparative avec score de propension. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Stefan D, Lesueur P, Lequesne J, Coquan E, Brachet P, Castera L, Goardon N, Lacroix J, Lange M, Capel A, Andre B, Grellard JM, Clarisse B. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high-grade gliomas patients: OLA-TMZ-RTE-01. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy273.394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Lecomte Dumont D, Stefan D, Sichel F, Habrand JL, Laurent C. Résultats préliminaires de l’étude Paescart : prédiction de l’apparition d’effets secondaires cutanés tardifs après radiothérapie. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.08.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Lesueur P, Chevalier F, Stefan D, El Habr E, Chneiweiss H, Junier M, Saintigny Y. Évaluation du traitement multimodal–témozolomide, inhibiteurs de PARP et hadronthérapie–des cellules souches cancéreuses de glioblastome. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.08.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Tomaszewski A, Clarisse B, Geffrelot J, Dugue A, Lesueur P, Kammerer E, Lecomte D, Thariat J, Habrand J, Stefan D. Radiothérapie en conditions stéréotaxiques hypofractionnée des métastases cérébrales : étude rétrospective de l’efficacité et de la tolérance du schéma délivrant 30 Gy en trois fractions. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.08.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
20
|
Meyer E, Pasquier D, Stefan D, Bernadou G, Carrie C, Calais G, Théodore C, Bossi A, Hennequin C, Lagrange J, Dugue A, Clarisse B, Habrand J, Joly F. Radiothérapie stéréotaxique pour la prise en charge des métastases osseuses du cancer du rein : étude rétrospective du Groupe d’études des tumeurs urogénitales (Gétug). Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.07.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Demoor-Goldschmidt C, Claude L, Carrie C, Bolle S, Helfre S, Alapetite C, Jouin A, Padovani L, Ducassou A, Vigneron C, Le Prisé É, Huchet A, Stefan D, Kerr C, Nguyen TD, Truc G, Chapet S, Bondiau PY, Coche B, Muracciole X, Laprie A, Noël G, Leseur J, Habrand JL, Potet H, Ruffier A, Supiot S, Mahé MA, Bernier V. [French organization of paediatric radiation treatment: Results of a survey conducted by the radiotherapy Committee of the French Society of Paediatric Cancers (SFCE)]. Cancer Radiother 2016; 20:395-9. [PMID: 27421622 DOI: 10.1016/j.canrad.2016.05.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2016] [Revised: 04/22/2016] [Accepted: 05/06/2016] [Indexed: 11/29/2022]
Abstract
PURPOSE Radiotherapy is a rare indication in paediatric oncology, with 800 to 900 children in treatment per year in France. Child cancers represent approximately 1% of cancers in France and half occur before the age of 5 years. Paediatric radiation requires appropriate tools, local, time and specific training. In France, in 2015, 18 centres are accredited by the French National Cancer Institute (INCa) for this activity. MATERIAL AND METHODS Survey conducted in February 2015 on the care of children (0 to 18 years) in radiotherapy departments in France. The survey was sent to the radiation oncologists involved in the 18 centres. The questions concerned the qualitative and quantitative aspect, medical and organizational aspects, and the involvement of assistant practitioners in the management of this activity. RESULTS Seventeen centres responded. In 2014, 889 children under 18 were treated in radiotherapy departments. These departments are working together with one to four paediatric oncology departments. Regarding access to general anaesthesia: three centres perform one to seven treatment(s) under anaesthesia per year, three centres eight to ten treatments under anaesthesia per year, three centres ten to 24 treatments under anaesthesia per year and nine centres out of 17 use hypnosis techniques. In terms of human resources, in 2015, 29 radiation therapists have a paediatric radiotherapy activity. Involvement of assistant practitioners is growing and specific training are desired. Regarding treatment preparation and delivery, 13 centres have specific paediatric contentions, 14 of 16 centres employ radiation intensity modulated if dosimetry is more satisfying with 11 regularly to the craniospinal irradiation. Radiotherapy on moving areas with respiratory gating or hypofractionation is under developed. CONCLUSION Paediatric radiation therapy is a specific activity requiring a dedicated management, both in human, organizational, medical and scientific aspects.
Collapse
Affiliation(s)
- C Demoor-Goldschmidt
- Radiothérapie, institut de cancérologie de l'Ouest-Nantes, boulevard Jacques-Monod, 44800 Saint-Herblain, France; Inserm U1018, rue Édouard-Vaillant, 94800 Villejuif, France.
| | - L Claude
- Radiothérapie, centre Léon-Bérard, 28, promenade Léa-et-Napoléon-Bullukian, 69008 Lyon, France
| | - C Carrie
- Radiothérapie, centre Léon-Bérard, 28, promenade Léa-et-Napoléon-Bullukian, 69008 Lyon, France
| | - S Bolle
- Radiothérapie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - S Helfre
- Radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - C Alapetite
- Radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - A Jouin
- Radiothérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59000 Lille, France
| | - L Padovani
- Radiothérapie, Assistance publique-Hôpitaux de Marseille, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France
| | - A Ducassou
- Radiothérapie, IUCT Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse, France
| | - C Vigneron
- Radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67000 Strasbourg, France
| | - É Le Prisé
- Radiothérapie, centre Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35000 Rennes, France
| | - A Huchet
- Radiothérapie, hôpital Haut-Lévêque, CHU de Bordeaux, avenue de Magellan, 33604 Pessac, France
| | - D Stefan
- Radiothérapie, centre François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France
| | - C Kerr
- Radiothérapie, institut du cancer de Montpellier, 208, avenue des Apothicaires, 34298 Montpellier, France
| | - T-D Nguyen
- Radiothérapie, institut Jean-Godinot, 1, rue du Général-Koenig, 51100 Reims, France
| | - G Truc
- Radiothérapie, institut Georges-François-Leclerc, 1, rue du Professeur-Marion, 21000 Dijon, France
| | - S Chapet
- Radiothérapie, Corad, hôpital Bretonneau, CHRU de Tours, 2 boulevard Tonnellé, 37000 Tours, France
| | - P-Y Bondiau
- Radiothérapie, centre Antoine-Lacassagne, 33, avenue de Valombrose, 06100 Nice, France
| | - B Coche
- Radiothérapie, centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59000 Lille, France
| | - X Muracciole
- Radiothérapie, Assistance publique-Hôpitaux de Marseille, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France
| | - A Laprie
- Radiothérapie, IUCT Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse, France
| | - G Noël
- Radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67000 Strasbourg, France
| | - J Leseur
- Radiothérapie, centre Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35000 Rennes, France
| | - J-L Habrand
- Radiothérapie, centre François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France
| | - H Potet
- Radiothérapie, institut Jean-Godinot, 1, rue du Général-Koenig, 51100 Reims, France
| | - A Ruffier
- Radiothérapie, Corad, hôpital Bretonneau, CHRU de Tours, 2 boulevard Tonnellé, 37000 Tours, France
| | - S Supiot
- Radiothérapie, institut de cancérologie de l'Ouest-Nantes, boulevard Jacques-Monod, 44800 Saint-Herblain, France
| | - M-A Mahé
- Radiothérapie, institut de cancérologie de l'Ouest-Nantes, boulevard Jacques-Monod, 44800 Saint-Herblain, France
| | - V Bernier
- Radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67000 Strasbourg, France
| |
Collapse
|
22
|
Lecomte D, Stefan D, Habrand J. Comparaison dosimétrique entre tomothérapie et radiothérapie tridimensionnelle conformationnelle classique : impact sur l’homogénéité de dose aux vertèbres en croissance, et sur les organes de voisinage, chez l’enfant. Cancer Radiother 2015. [DOI: 10.1016/j.canrad.2015.07.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Bo L, Su-Ling D, Fang L, Lu-Yu Z, Tao A, Stefan D, Kun W, Pei-Feng L. Autophagic program is regulated by miR-325. Cell Death Differ 2014; 21:967-77. [PMID: 24531537 DOI: 10.1038/cdd.2014.18] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Revised: 12/31/2013] [Accepted: 01/14/2014] [Indexed: 12/31/2022] Open
Abstract
Autophagy is required for the maintenance of cardiomyocytes homeostasis. However, the abnormal autophagy could lead to the development of heart failure. Autophagy is enhanced during myocardial ischemia/reperfusion; it remains to elucidate the molecular regulation of autophagy. We report here that miR-325, ARC and E2F1 constitute an axis that regulates autophagy. Our results showed that miR-325 expression is upregulated upon anoxia/reoxygenation and ischemia/reperfusion. Cardiomyocyte-specific overexpression of the miR-325 potentiates autophagic responses and myocardial infarct sizes, whereas knockdown of miR-325 inhibited autophagy and cell death. We searched for the downstream mediator of miR-325 and identified that ARC is a target of miR-325. ARC transgenic mice could attenuate autophagy and myocardial infarction sizes upon pressure-overload-induced heart failure, whereas ARC null mice exhibited an increased autophagic accumulation in the heart. The suppression of ARC by miR-325 led to its inability to repress autophagic program. In exploring the molecular mechanism by which miR-325 expression is regulated, our results revealed that the transcription factor E2F1 contributed to promote miR-325 expression. E2F1 null mice demonstrated reduced autophagy and myocardial infarction sizes upon ischemia/reperfusion. Our present study reveals a novel autophagic regulating model that is composed of E2F1, miR-325 and ARC. Modulation of their levels may provide a new approach for tackling cardiac failure.
Collapse
Affiliation(s)
- L Bo
- Division of Cardiovascular Research, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
| | - D Su-Ling
- Division of Cardiovascular Research, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
| | - L Fang
- Division of Cardiovascular Research, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
| | - Z Lu-Yu
- Division of Cardiovascular Research, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
| | - A Tao
- FU WAI Hospital CAMS&PUMC, National Center for Cardiovascular Diseases, Beijing 10037, China
| | - D Stefan
- Franz-Volhard-Clinic, Humboldt University of Berlin, Berlin 13125, Germany
| | - W Kun
- Division of Cardiovascular Research, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
| | - L Pei-Feng
- Division of Cardiovascular Research, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
| |
Collapse
|
24
|
Habrand JL, Datchary J, Alapetite C, Bolle S, Calugaru V, Feuvret L, Helfre S, Stefan D, Delacroix S, Demarzi L, Dendale R. Évolution des indications cliniques en hadronthérapie 2008–2012. Cancer Radiother 2013; 17:400-6. [DOI: 10.1016/j.canrad.2013.07.141] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2013] [Accepted: 07/16/2013] [Indexed: 12/25/2022]
|
25
|
Stefan D, Leverne Williams H, Renton DR, Pintar MM. Proton spin relaxation in bisphenol-a polycarbonate, butyl rubber, and their composites. J MACROMOL SCI B 2011. [DOI: 10.1080/00222347008217127] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- D. Stefan
- a Department of Chemical Engineering and Applied Chemistry , University of Toronto , Toronto, Ontario , Canada
| | - H. Leverne Williams
- a Department of Chemical Engineering and Applied Chemistry , University of Toronto , Toronto, Ontario , Canada
| | - D. R. Renton
- b Department of Physics , University of Waterloo , Waterloo, Ontario, Canada
- c Dunlop Research Centre , Sheridan Park, Ontario, Canada
| | - M. M. Pintar
- b Department of Physics , University of Waterloo , Waterloo, Ontario, Canada
| |
Collapse
|
26
|
Căruntu F, Dogaru D, Stefan D, Căruntu V, Angelescu C, Streinu-Cercel A, Colţan G, Petrescu AL, Tarţă D, Bârnaure F. Value of serological tests in the diagnosis of viral acute respiratory infections in adults. Virologie (Montrouge) 1986; 37:83-7. [PMID: 3727398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The dynamics of the antibody response to influenza viruses A (H1N1), A (H3N2) and B, to parainfluenza viruses 1, 2, 3, to adenoviruses and respiratory syncytial virus was studied in paired serum samples collected from 110 patients hospitalized with acute respiratory infections (ARI) and in 40 patients suffering from other diseases. Rises in serum antibody titers to 1--5 of the above mentioned antigens were detected in many of the patients of both groups. The fact is most likely due to the presence of some epidemiologically and clinically uncharacteristic viral ARI (influenza included); simultaneous or successive infections with influenza virus and different other viruses were very frequent. A greater efficiency of the etiological diagnosis of viral ARI can be achieved only by the association of epidemiological and clinical criteria with serological data, the visualization of viral antigens and virus isolation.
Collapse
|
27
|
Gherman I, Enuică V, Stefan D. [Value of some immunological diagnostic methods in hydatid disease (original technical adaptations)]. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna 1984; 36:277-82. [PMID: 6151736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
28
|
Dogaru D, Ispas LT, Cernica L, Nicolau G, Stefan D. [Severe bacterial pneumonia in adults. Clinical and therapeutic aspects of 61 cases]. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol 1984; 33:163-72. [PMID: 6093223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
29
|
|
30
|
Popescu D, Litarczek G, Stefan D. The organisation of the postoperative and intensive care units in the clinical hospital Fundeni. Acta Anaesthesiol Scand Suppl 1966; 23:123-9. [PMID: 6003626 DOI: 10.1111/j.1399-6576.1966.tb01002.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|